BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35309367)

  • 1. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.
    Peinelt A; Bremm M; Kreyenberg H; Cappel C; Banisharif-Dehkordi J; Erben S; Rettinger E; Jarisch A; Meisel R; Schlegel PG; Beck O; Bug G; Klusmann JH; Klingebiel T; Huenecke S; Bader P
    Front Immunol; 2022; 13():830773. PubMed ID: 35309367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect staining.
    Zaninelli S; Meli C; Borleri G; Quaroni M; Pavoni C; Gaipa G; Biondi A; Introna M; Golay J; Rambaldi A; Rambaldi B
    Cytometry A; 2024 Feb; 105(2):112-123. PubMed ID: 37707318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
    Gauthier J; Turtle CJ
    Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique.
    Valdivieso-Shephard JL; Matas-Pérez E; García-Bujalance S; Mirones-Aguilar I; González-Martínez B; Pérez-Martínez A; López-Granados E; Martínez-Feito A; Sánchez-Zapardiel E
    Cytometry A; 2024 May; 105(5):368-375. PubMed ID: 38327134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
    Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
    Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
    Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories.
    Johansson U; Gallagher K; Burgoyne V; Maus MV; Casey KS; Brini GG; Frigault MJ; Yam JY; Chavda N; Besley C; Lugthart S
    Cytometry B Clin Cytom; 2021 Nov; 100(6):622-631. PubMed ID: 33915021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 17. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
    García-Calderón CB; Sierro-Martínez B; García-Guerrero E; Sanoja-Flores L; Muñoz-García R; Ruiz-Maldonado V; Jimenez-Leon MR; Delgado-Serrano J; Molinos-Quintana Á; Guijarro-Albaladejo B; Carrasco-Brocal I; Lucena JM; García-Lozano JR; Blázquez-Goñi C; Reguera-Ortega JL; González-Escribano MF; Reinoso-Segura M; Briones J; Pérez-Simón JA; Caballero-Velázquez T
    Front Immunol; 2023; 14():1152498. PubMed ID: 37122702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.